Knowledge base · October 2, 2026 · Updated October 10, 2026 · Stefan Bensmo

When Regulatory Risk Becomes Real: Turning Point Brands and the Pouch That Became a Third of the Company

Let's be clear about what this isn't: neither Turning Point Brands nor its nicotine pouch brand Fre has shut down. What's happened is something more directly useful for anyone planning a US push — a publicly traded company has shown, in real time over six months, exactly what it costs when growth is built too fast on a single product category awaiting a regulatory decision it doesn't control.

The growth that built the dependency

Turning Point Brands (TPB), listed on the NYSE, is a longstanding US tobacco company that has expanded heavily into nicotine pouches through its Fre brand. In the first quarter of 2026, Fre grew 266% year over year to $41.3 million in quarterly revenue — which alone made up 34% of the company's total revenue. That's the kind of growth figure that makes an investor presentation look unimpeachably strong.

The pullback: when the FDA slowed down

During the week starting April 3, 2026, TPB's stock fell 15.5%, trading roughly 50% below its 52-week high of $146.90. The cause financial media pointed to wasn't a single decision but a pattern: the FDA appeared reluctant to grant new PMTA authorizations for nicotine pouches, citing concerns about health effects and youth usage — see our breakdown of the PMTA process for how that mechanism works. A company that had built a third of its revenue on exactly that category saw it hit the stock price directly.

The second hit: leadership, guidance and competition at once

On September 21, 2026, the stock fell another 10% in a single day. This time the primary causes were different: CEO Graham Purdy's unexpected resignation effective October 1 (stated reason: personal reasons, with executive chairman David Glazek as incoming replacement) and a cut to full-year EBITDA guidance — from a previous high end of $90 million, revised down to $70 million. The same coverage also pointed to competitive pressure from Zyn Ultra, which the FDA had authorized for a Philip Morris-affiliated company on August 21, 2026 — a factor on top of the other causes, but not described as the primary one.

Our read It's crucial not to lump the two events into a single "FDA-caused crisis" — that would misrepresent what the sources themselves say. What they show together is something broader: a company heavily concentrated in a fast-growing but regulatorily unpredictable category has several independent ways to become vulnerable at once, and the market punishes each one as it materializes.

What it means for you

• A third of revenue in a category awaiting a regulatory decision is a visible risk, not a hidden one. Investors and analysts price it in — make sure your own plan does too, with scenarios for delay.
• Concentration risk is cumulative, not binary. TPB was hit twice for different reasons in six months. Build resilience against several kinds of shocks, not just the one you currently judge most likely.
• Track competitors' authorization pace, not just your own. A competitor jumping the PMTA queue is itself a risk to your growth plan, regardless of where your own application stands.

We help stress-test a growth plan against regulatory risk before it becomes an investor question — see board and management support.